Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07115706

JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive GERD

The purpose of this study is to evaluate the effectiveness and safety of JAQBO® Tab. 20 mg(Zastaprazan citrate) patients who have been prescribed the investigational drug.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Erosive Gastroesophageal Reflux Disease

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Multi-center prospective observational study

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • subjects aged 19 years or older who have been diagnosed with erosive reflux disease (ERD)
  • subjects who have voluntarily decided to participate in this observational study and have provided written informed consent after receiving the study information and consent form

Exclusion criteria

  • Subjects who fall under the contraindications listed in the precautions for use section of the approved labeling for Fexuclu tablets:
  • Subjects with hypersensitivity or a history of hypersensitivity to the investigational drug or any of its components
  • Subjects currently taking medications containing atazanavir, nelfinavir, or rilpivirine
  • Pregnant women, women who may be pregnant, or breastfeeding women
  • Subjects with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
  • Subjects deemed inappropriate for participation in the study at the investigator's discretion.

Treatment and study plan

Primary outcomes

  1. Change in Reflux Disease Questionnaire (RDQ) at Week 8

    Time frame: Week 8

    This questionnaire is a self-reported instrument designed to assess the main symptoms of gastroesophageal reflux disease (GERD), including heartburn, acid regurgitation, and dyspepsia. It consists of a total of 12 items, each evaluating the frequency and severity of symptoms using a 6-point scale (0 to 5). In this observational study, only heartburn and acid regurgitation symptoms are assessed. The questionnaire is completed by the study participants themselves, and higher total scores indicate more severe symptoms.

Study contacts

Contact information is provided by the study sponsor or research team.

Minjeong Kim

CONTACT

[email protected]

+82 2-549-7451 ext. 542

Sponsors and collaborators

Lead sponsor

Jeil Pharmaceutical Co., Ltd.

Industry

Registry information

Official study title

A Multi-center Prospective Observational Study to Evaluate the Effectiveness and Safety of JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive Gastroesophageal Reflux Disease

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Aug 11, 2025
Registry last updated
Aug 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.